LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Results of Operations and Financial ConditionItem 2.02RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On July 27, 2017, La Jolla Pharmaceutical Company issued a press release announcing its financial results for the three and six months ended June 30, 2017. A copy of the press release is furnished as Exhibit 99.1. The press release should be read in conjunction with the note regarding forward looking statements, which is included in the text of the press release.
The information in this Item 2.02 and in Exhibit 99.1 will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 2.02FINANCIAL STATEMENTS AND EXHIBITS.
(d)Exhibits. The following exhibits are furnished with this report on Form 8-K:
|
Exhibit No. |
Description |
|
99.1 |
Earnings Press Release dated July 27, 2017. |
LA JOLLA PHARMACEUTICAL CO ExhibitEX-99.1 2 exhibit2q17.htm EXHIBIT 99.1 Exhibit La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30,…To view the full exhibit click here
About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
